Patrick Campbell

The FDA has cleared Sequel's twiist, a novel automated insulin delivery system, expanding patient choice for individuals with type 1 diabetes.

Silence Therapeutics' announcement of topline data from the ALPACAR-360 trial shows promising results for zerlasiran in reducing Lp(a) levels.

On March 15, 2024, the FDA approval of fluticasone propionate nasal spray marks the first approval in agency history for treatment of chronic rhinosinusitis without nasal polyps.

To acknowledge World Kidney Day, our latest episode of Crisis Point focuses on the stigma surrounding the use of HCV-positive donor kidneys amid the ongoing organ shortage crisis, with the perspective of a pair of experts and an HCV donor kidney recipient.

A new study suggests a next-generation stool DNA test from Exact Sciences has improved sensitivity for colorectal cancer and precancerous lesions but lower specificity than FIT.

New data from the Family Heart Foundation highlights low access to PCSK9 inhibitors due to insurance rejections, despite guidelines recommending their use for high-risk patients.

Eiran Gorodeski, MD, MPH, discusses a recent scientific statement composed on behalf of the Heart Failure Society of America highlighting the impact of cognitive impairment on patients with heart failure.

Study links childhood amblyopia with increased risk of cardiometabolic dysfunction in adulthood.

Nearly a decade after becoming the first PCSK9 inhibitor to receive approval from the FDA, alirocumab (Praluent) has now received approval for pediatric patients with HeFH based on data from a phase 3 trial.

On March 08, 2024, the FDA approved semaglutide 2.4 mg (Wegovy) to reduce cardiovascular risk in adults with obesity or overweight and heart disease based on the SELECT trial.

An analysis of the Strong Heart Family Study details High rates of dyslipidemia in American Indian youth and young adults, with more than 70% of those 15-39 years old affected.

On March 07, 2024, Novo Nordisk provided updates on semaglutide 2.4 mg as well as the development programs cagrisema, monlunabant, and amycretin.

On March 07, 2024, Boehringer Ingelheim announced it would be instituting a $35 per month out-of-pocket cost cap for its portfolio of inhaler products, with this cap going into effect on June 01, 2024.

In our endocrinology month in review for February 2024, we are spotlighting trending studies and new data in endocrinology, the latest news surrounding tirzepatide, and a recap of the 4 episodes of our flagship endocrinology podcast launched during the last month.

A study suggests that opting for thyroid surgery or radioactive iodine therapy could be better for reducing long-term cardiovascular risk in hyperthyroidism patients compared to medication alone.

The FDA has greenlit Dexcom's Stelo Glucose Biosensor System, marking a historic first as the first continuous glucose monitors to be available over-the-counter.

Results of a new analysis underscore the significance of sleep health in mitigating type 2 diabetes risk, revealing that even an optimal diet may not fully offset the negative impact of inadequate sleep.

Novo Nordisk announced topline data from the FLOW trial indicate semaglutide 1.0 mg (Ozempic) was associated with a 24% reduction in risk of kidney disease-related events among individuals with type 2 diabetes and CKD compared to placebo therapy.

The latest analysis of the Mass General Brigham Lp(a) Registry highlights Lp(a)'s independent association with cardiovascular events, with these associations apparent in patients regardless of baseline cardiovascular history.

Our February 2024 cardiology month in review, recaps FDA news, top data from International Stroke Conference and major journals, and perspectives form a bevy of key opinion leaders in the field on hot topics and news from across the spectrum of cardiovascular medicine.

The approval of the AGENT Drug-Coated Balloon is based on the AGENT IDE trial and was announced by Boston Scientific on March 01, 2024.

Viking Therapeutics' dual GLP-1/GIP receptor agonist VK2735 showed promising weight reduction in the phase 2 VENTURE trial, with the 15 mg dose contributing to a 14% reduction in body weight from baseline to week 13.

Deepak Bhatt, MD, MPH, looks ahead to discuss what he is most excited about from the upcoming late-breaking clinical trials sessions at the American College of Cardiology 2024 annual meeting

Viaskin milk patch shows promise in cow’s milk allergy, particularly in children aged 2-11 with 300 μg dose, though the other doses examined failed to prove significant benefit.

Survodutide, a dual agonist from Boehringer Ingelheim and Zealand Pharma, was associated with MASH resolution without worsening fibrosis among 83% of participants in a phase 2 trial.

Robert Wood, MD, principal investigator of the OUtMATCH trial, offers insight into the trial and its results beyond the primary outcome, with a focus on what it means for patients and providers.

Omalizumab, the only FDA-approved treatment for multiple food allergies, demonstrated significant efficacy in the OUtMATCH trial, with 67% achieving the primary outcome compared to 7% in the placebo group.

Rilzabrutinib, an oral BTK inhibitor, demonstrates efficacy in reducing itch and disease activity among patients with chronic spontaneous urticaria in phase 2 dose-ranging trial at AAAAI 2024.

The MANDARA trial results, published in NEJM, show benralizumab's noninferiority to mepolizumab in eosinophilic granulomatosis with polyangiitis, with potential for oral glucocorticoid discontinuation.

Robert Wood, MD, discusses how the FDA approval of omalizumab (Xolair) changes the management of pediatric food allergy and what type of hurdles to optimal uptake the community may encounter.